Axcella Health Inc AXLA:NASDAQ

Last Price$1.61NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.17(9.55%)
Bid (Size)$1.20 (2)
Ask (Size)$1.75 (5)
Day Low / High$1.45 - 1.79
Volume144.2 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Axcella Health Inc ( NASDAQ )

Price: $1.61
Change: -0.17 (9.55%)
Volume: 144.2 K
4:00PM ET 1/21/2022
 
 

Astria Therapeutics Inc ( NASDAQ )

Price: $4.83
Change: -0.06 (1.23%)
Volume: 15.4 K
3:59PM ET 1/21/2022
 
 

Avalon Globocare Corp ( NASDAQ )

Price: $0.74
Change: +0.02 (2.27%)
Volume: 113.9 K
4:00PM ET 1/21/2022
 
 

T2 Biosystems Inc ( NASDAQ )

Price: $0.39
Change: -0.008 (1.95%)
Volume: 2.3 M
4:00PM ET 1/21/2022
 
 

Orgenesis Inc ( NASDAQ )

Price: $2.70
Change: +0.13 (5.06%)
Volume: 70.6 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Chardan Research Lifts Axcella Health's Price Target to $12 From $10; Buy Rating Kept
8:48AM ET 11/16/2021 MT Newswires

Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $5 to $28, according to analysts polled by Capital IQ. (MT...

-- Earnings Flash (AXLA) AXCELLA THERAPEUTICS Posts Q3 Loss $-0.41
7:58AM ET 11/10/2021 MT Newswires

...

Noble Capital Initiates Axcella Health at Outperform Rating With $6 Price Target
11:51AM ET 10/12/2021 MT Newswires

Axcella Health (AXLA) has an average outperform rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires...

Goldman Sachs Downgrades Axcella Health to Neutral Rating From Buy, Adjusts Price Target to $5 From $9
8:37AM ET 9/22/2021 MT Newswires

Axcella Health (AXLA) has an average outperform rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires...

Company Profile

Business DescriptionAxcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address840 Memorial Drive
Cambridge, Massachusetts 02139
Phone+1.857.320.2200
Number of Employees49
Recent SEC Filing01/20/20224
President, Chief Executive Officer & DirectorWilliam R. Hinshaw
Chief Scientific Officer, Senior VP-R&DTony Tramontin
Chief Medical Officer & Senior Vice PresidentMargaret Koziel
President-Research & DevelopmentAlison Schecter

Company Highlights

Price Open$1.79
Previous Close$1.78
52 Week Range$1.45 - 6.84
Market Capitalization$62.7 M
Shares Outstanding38.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/16/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.64
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-112.24%

Analyst Ratings as of 12/16/2021

Buy
7
Overweight
0
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset